Imugene Ltd · ASX:IMU

Imugene — Investor Presentation (July 2017)

40 slides from Imugene's investor presentation, July 2017

  1. Slide 1: Mimotope Induced B-Cell Antibodies for Immuno-Oncology

    ASX:IMU v MIMOTOPE INDUCED B-CELL ANTIBODIES FOR IMMUNO-ONCOLOGY Leslie Chong | Chief Executive Officer 2H/2017 -1-

  2. Slide 2: Notice: Forward Looking Statements

    NOTICE: FORWARD LOOKING STATEMENTS Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other fa

  3. Slide 3: What Does Imugene Do?

    WHAT DOES IMUGENE DO? Imugene’s technology can induce a patient’s body v to make its own specific antibodies that target cancer. -3-

  4. Slide 4: Executive Summary

    EXECUTIVE SUMMARY • Two novel oncology platforms: B cell mimotope vaccines and small molecule arginine modulator • Lead mimotope: HER-Vaxx Phase 1b/2 mimotope study in Her-2+ gastric cancer about to commence • POC demonstrated in Phase 1 Her-2+ breast cancer study – safety & immunogenecity establish

  5. Slide 5: A Better Way to Make Antibodies to Treat Cancer?

    A BETTER WAY TO MAKE ANTIBODIES TO TREAT CANCER? IN A FACILITY USING B CELLS IN YOUR OWN BODY B Cells are cells in the human VSv body that naturally produce millions of antibodies Teaching B cells to make antibodies For example, Roche’s Herceptin using peptide mimotopes -5-

  6. Slide 6: Two Mimotope Peptide Programs and Commercial Opportunities

    TWO MIMOTOPE PEPTIDE PROGRAMS AND COMMERCIAL OPPORTUNITIES • A mimotope is a small molecule, often a peptide, which mirrors the structure of an epitope, the specific target an Peptides identified antibody binds to. via computer aided • Because of this property, the mimotope induces an programs: HER-

  7. Slide 7: Mimotope: Platform Technology

    MIMOTOPE: PLATFORM TECHNOLOGY SELECTION OF MIMOTOPES CREATION OF A VACCINE IMMUNIZATION ENDOGENOUS AB PRODUCTION A library of mimotopes The selected mimotope or Immunization with the Successful delivery will result in can be interrogated with mimotopes can be used in peptide will lead to endogenous

  8. Slide 8: Advantages of Mimotope Induced B-Cell Based Antibodies v. Synthetic Antibodies

    ADVANTAGES OF MIMOTOPE INDUCED B-CELL BASED ANTIBODIES V. SYNTHETIC ANTIBODIES Issue Natural B Cell Derived Antibodies Monoclonal Antibodies Safety Stimulates the immune system to produce natural Synthetic Ab, with side effects (including ventricular Abs, potentially safer, as demonstrated by HER-Va

  9. Slide 9: The Monoclonal Antibody (mAb) Market

    THE MONOCLONAL ANTIBODY (mAb) MARKET • Multiple antibody therapies are approved to treat cancer, for example: Sales in 2016 - Herceptin: >US$6.7 billion - Perjeta: >US$1.8 billion - Rituxan: >US$7.3 billion - YERVOY®: >US$1.0 billion - OPDIVO®: >US$3.7 billion - KEYTRUDA: >US$1.4 billion v Total mon

  10. Slide 10: HER-Vaxx Mimotope: Mechanism of Action

    HER-Vaxx MIMOTOPE: MECHANISM OF ACTION Peptides “mimic” the HER-Vaxx epitope Antibody Secretion Tumor Cell 3 B-cell HER-2/neu EPITOPE = Peptides v Activation Antibody Via helper T- Binding Site cells B-Cell HER-Vaxx attacks the same target as the HER-Vaxx the world’s largest Immunotherapy selling br

  11. Slide 11: HER-Vaxx Phase 1b/2 Mimotope Peptide Therapy for HER2+ Gastric Cancer

    ASX:IMU v HER-VAXX IS A Phase 1b/2 STAGE MIMOTOPE PEPTIDE THERAPY BEING DEVELOPED FOR HER2+ GASTRIC CANCER - 11 -

  12. Slide 12: Phase 1 in Breast Cancer, Completed at Medical University of Vienna

    PHASE 1 IN BREAST CANCER, COMPLETED AT MEDICAL UNIVERSITY OF VIENNA- SINGLE AGENT, NO CHEMO DESIGN RESULTS CLINICAL ENDPOINTS • 10 patients • Patients developed anti-HER-2 antibodies 1 Safety and Tolerability • All late stage breast cancer • Induction of cytokines (Th1 biased; IFNγ) patients • Induc

  13. Slide 13: HER-Vaxx Has Been Optimised Since Phase 1a Breast Cancer Study

    Ph1b/2 HER-VAXX HAS BEEN OPTIMISED SINCE Formulation PHASE 1A BREAST CANCER STUDY 3rd Generation 2nd Generation • Changed the delivery system from virosomes to CRM197 • Incorporated the three B Cell (which gave CD4 T-Helper epitopes into a vsingle 49-mer response), and added a 1st Generation peptide

  14. Slide 14: HER-Vaxx Inhibits HER-2 Expressing Cells

    HER-VAXX INHIBITS HER-2 EXPRESSING CELLS • HER-Vaxx antibodies demonstrate anti-tumour effect by inhibiting HER-2+ gastric and breast cancer cell lines • Combination with Herceptin v shows significantly higher inhibition than Herceptin alone. HER-2+ gastric cancer cells* HER-2+ breast cancer cells *

  15. Slide 15: Phase 1b/2, in Gastric Cancer

    PHASE 1B/2, IN GASTRIC CANCER Phase 1b lead-in Phase 2 • Open label • Open label • ~Up to 18 patients in 3 cohorts of up to 6 pts per • ~68 patients from sites in Asia cohort • Combination with chemo • Combination with chemo/cisplatin • Randomized • Endpoints: • Primary Endpoints: - Recommended Phas

  16. Slide 16: Gastric Market Opportunity

    GASTRIC MARKET OPPORTUNITY • Asia is the largest market for gastric cancer globally • Gastric cancer is the second leading cause of cancer mortality in the world & its management, especially in advanced stages, has evolved Chemotherapy relatively little • ~20% patients with metastatic gastric cancer

  17. Slide 17: Mimotope B-Cell Peptide Therapy

    ASX:IMU v MIMOTOPE B-CELL PEPTIDE THERAPY - 17 -

  18. Slide 18: Mimotope Proposed Development Path 2017-2018

    MIMOTOPE PROPOSED DEVELOPMENT PATH 2017-2018 2H, 2018:Toxicology, 2H, 2018: GMP 2H, 2017 : 1H, 18:Formal pre- immunotox, safety Mimotope Candidate manufacturing clinical pharmacology (cont. dev of 2-3 1H, 2018: CMC additional candidate) manufacturing v Proposed Phase l Cohort 5 Expansions Assumption

  19. Slide 19: Arginine Modulators

    ASX:IMU v ARGININE MODULATORS - 19 -

  20. Slide 20: Secondary Technology Platform: First-in-Class Small Molecule Arginine Modulators – A12

    SECONDARY TECHNOLOGY PLATFORM FIRST-IN-CLASS SMALL MOLECULE ARGININE MODULATORS – A12 • Arginine is a critical amino acid for the health of cancer fighting T- cells and depletion of it limits the effectiveness of T-cells to fight tumors • IMU’s A12 molecule increase the availability of arginine in t

  21. Slide 21: Arginine Proposed Development Path 2017-2018

    ARGININE PROPOSED DEVELOPMENT PATH 2017-2018 Given that Arginine is a critical amino acid for the health of Syngeneic mouse models cancer fighting T-cells: Cell line Cancer Type • In vitro effect of lead compound on human PBMC’s will H22 Liver readout T-cell cytokine changes MC38 Colon • Flow cytome

  22. Slide 22: A Team with Track Record in Drug Development

    A TEAM WITH TRACK RECORD IN DRUG DEVELOPMENT Leslie Chong Prof Ursula Wiedermann Chief Executive Officer Chief Scientific Officer • Over 19 years of oncology experience in Phase I - III of • Co-inventor of Her-Vaxx; clinical program development • Professor of Vaccinology at Medical University of • L

  23. Slide 23: Business Strategy and Partnering Opportunities

    BUSINESS STRATEGY AND PARTNERING OPPORTUNITIES 2018 2018-2019 2018-2020 Phase 1b Big Pharma Phase 1b Mimotope + v and/or biotech? Gastric Study others - 23 -

  24. Slide 24: Financial Summary

    FINANCIAL SUMMARY ASX:IMU Top 5 shareholders (as at May. 2017) Market Cap No. of Shares % Capital $33.1M AUD, $25.7M USD (14/Jul/17) Platinum Asset Ordinary Shares 2.365 billion 240,227,753 10.16% Management 12 month price National Nominees 0.7 cents – 2.1 cents AUD 95,548,708 4.04% range Limited Av

  25. Slide 25: 36 Month Targets and Investor Deliverables

    36 MONTH TARGETS AND INVESTOR DELIVERABLES HER-VAXX MIMOTOPES ARGININE MODULATORS 3-4 mimotope candidates. Move at Definitive clinical least two mimotope Candidate selection data package from a Phase 1b and Phase 2 trial in gastric + candidatesvfrom pre- clinical to IND enabled + Develop at least on

  26. Slide 26: Imugene Pipeline

    IMUGENE PIPELINE MIMOTOPE IMMUNE ID OF PROGRAM PRE-IND WORK CLINICAL DEVELOPMENT IDENTIFICATION CHARACTERIZATION CANDIDATE HER-Vaxx HER-Vaxx /Her2 Combo *Mimotope #2 *Mimotope #3 v Her2 / *Mimotope Combo Combo #3? TBD DISCOVERY ID OF CANDIDATE PRE-IND WORK Arginine Modulator - 26 -

  27. Slide 27: Executive Summary

    EXECUTIVE SUMMARY • Two novel oncology platforms: B cell mimotope vaccines and small molecule arginine modulator • Lead mimotope: HER-Vaxx Phase 1b/2 mimotope study in Her-2+ gastric cancer about to commence • POC demonstrated in Phase 1 Her-2+ breast cancer study – safety & immunogenecity establish

  28. Slide 28: Appendix

    ASX:IMU APPENDIX v SR. TEAM MEMBER ON MARKETED ONCOLOGY DRUGS - 28 -

  29. Slide 29: Herceptin (Trastuzumab) Mild Treatment Related Side Effects

    HERCEPTIN ® (TRASTUZUMAB) MILD TREATMENT RELATED SIDE EFFECTS • Diarrhea • Redness or irritation at injection (IV) site • Muscle/joint/back pain • Stomach or abdominal pain v • Headache • Sleep problems (insomnia) • Nausea and vomiting (may be severe) • Weight loss - 29 -

  30. Slide 30: Herceptin (Trastuzumab) Serious Treatment Related Side Effects

    HERCEPTIN ® (TRASTUZUMAB) SERIOUS TREATMENT RELATED SIDE EFFECTS – BLACK BOX WARNING1 • CARDIOMYOPATHY: Herceptin can result in sub-clinical and clinical cardiac failure manifesting as CHF (congestive heart failure), and decreased LVEF ( left ventricular ejection fraction). • INFUSION REACTIONS: PUL

  31. Slide 31: Phase 1a Study Design

    PHASE IA STUDY DESIGN* ADMINISTRATION & READOUT SCHEDULE Patient inclusion criteria • Metastatic breast cancer • HER2 +, ++ • ER/PR pos. • Life expectance > 4 mo v Primary endpoint D0 D28 D56 D84 • Safety & Tolerability Secondary endpoint Vaccination with 10µg • Immunogenicity of each peptide antige

  32. Slide 32: Patient Characteristics – Ages 55-84

    PATIENT CHARACTERISTICS – AGES 55-84 * Patient ID Age Metastatic disease since Prior chemotherapy Current antihormonal therapy 1 55 Oct. 2006 no Anastrozol 2 66 May 2004 yes (1 adj) Fulvestrant 3 84 Mar. 1999 no Anastrozol 4 79 Sept. 2003 no Anastrozol 5 67 Apr. 2004 no Fulvestrant v 6 69 Sept. 2004

  33. Slide 33: Safety and Tolerability – Few Grade 1 Local Reactions, None Systemic

    SAFETY AND TOLERABILITY – FEW GRADE 1 LOCAL REACTIONS, NONE SYSTEMIC* Patient ID Local vaccination reaction grade Systemic grade 3/4 toxicity 1 1 no 2 0 no 3 0 no 4 1 no 5 1 v no 6 0 no 7 0 no 8 0 no 9 1 no 10 0 no * Breast Cancer Res Treat. 2010 Feb;119(3):673-83. - 33 -

  34. Slide 34: Phase 1 Secondary Endpoint – Immunologic Responses

    PHASE 1 SECONDARY ENDPOINT – IMMUNOLOGIC RESPONSES Western blot analysis demonstrating increase of Her-2/neu-specific IgG post- vaccination in patient: ANTIBODY (lane 1) Polyclonal rabbit anti Her-2/neu antibody was used as positive control RESPONSES (lane 2) serum of a healthy volunteer as negative

  35. Slide 35: Phase 1 – Reduction in Regulatory T Cells

    Cancer PatientsPhase vs. Healthy Controls I - Regulatory T cells: Cancer Patients vs. Healthy Controls REDUCTION IN REGULATORY T CELLS* p=0.033 pre-vaccination post-vaccination p=0.033 pre-vaccination post-vaccination CD4+Foxp3+ Data.026 CD4+Foxp3+ Data.026 10.0 p=0.007 p=0.007 10.0 1.06 8.32 1.06 8

  36. Slide 36: Encouraging Immunogenicity, Even at Low Dose, in Patients Up to 84 Years

    ENCOURAGING IMMUNOGENICITY, EVEN AT LOW DOSE, AND IN PATIENTS AGES UP TO 84 YEARS, WITH NO CARDIOTOXICITY Antibody and cellular responses in human Pat. # Peptide-specific ab P4, P6, P7 HER2- specific ab Infl. HIT IL-2, IFNγ, TNF T reg • Immunogenicity in 8/10 patients in Phase 1 study with 10 µg of

  37. Slide 37: Tumor Growth Inhibition In Vivo

    TUMOR GROWTH INHIBITION IN VIVO* Time to disease progression • Prolonged time to Cumulative proportion tumor-free Untreated Tentanus toxoid disease progression Peptide Peptide + IL12 • Immunization of c-neu transgenic mice IL12 (recognized HER2 cancer model) with tetanus toxoid-conjugated peptides P

  38. Slide 38: Mimotope

    MIMOTOPE Peptides “mimic” the epitope EPITOPE = Antibody Binding Site HER2+ Cancer v Cell Mimotope Anti HER-2 Peptides Patient’s B Cells Antibody make antibodies B-Cell against HER-2 HER-2 Receptor - 38 -

  39. Slide 39: Phase 1b/2 Enhanced Gastric Formulation

    PHASE 1B/2 ENHANCED GASTRIC FORMULATION Her-2/neu specific IgG kinetic, after last immunization 1.60 3 w. after 3 doses vacc. 1.40 1.20 8 w. after 3 doses vacc. 1.00 16 w. after 3 doses vacc. 0.80 6 mo. after 3 doses vacc. OD v 0.60 Pre-immunization 0.40 0.20 0.00 P467-CRM-Montanide (µg) In the mous

  40. Slide 40: Leslie Chong

    Leslie Chong Chief Executive Officer leslie.chong@imugene.com v +61 458 040 433 - 40 -

Imugene — Investor Presentation (July 2017) on 6ix